DESTINY-Breast09 Redefines First-Line HER2-Positive Breast Cancer: Balancing Efficacy, Safety, and Treatment Selection

The phase III DESTINY-Breast09 trial has fundamentally changed first-line treatment options for HER2-positive metastatic breast cancer, establishing trastuzumab deruxtecan (T-DXd) plus pertuzumab as a highly effective alternative to the longstanding taxane–trastuzumab–pertuzumab (THP) regimen. With median progression-free survival exceeding three years, the combination provides an important opportunity to improve disease control. However, translating these results into clinical practice requires more than adopting a new preferred regimen: treatment selection must account for disease burden, intracranial involvement, prior therapy, comorbidities, cumulative toxicity, and evolving maintenance strategies.

Published in the New England Journal of Medicine, DESTINY-Breast09 demonstrated that T-DXd plus pertuzumab significantly improved progression-free survival (PFS) compared with THP in previously untreated HER2-positive advanced or metastatic breast cancer.

Median PFS reached 40.7 months with T-DXd plus pertuzumab compared with 26.9 months with THP, corresponding to a hazard ratio (HR) of 0.56 (95% CI 0.44–0.71; p<0.00001). The results represent a 44% relative reduction in the hazard of progression or death and an absolute difference of 13.8 months in median PFS.

The findings supported US Food and Drug Administration approval on December 15, 2025, followed by European Union authorization on September 1, 2026, establishing the regimen as an approved first-line option in both jurisdictions. Additional evidence presented at ESMO Congress 2026 further strengthened the clinical rationale by demonstrating encouraging systemic and intracranial disease control among patients with baseline brain metastases.

Yet important questions remain. Overall survival (OS) data are immature, interstitial lung disease (ILD) remains a potentially serious treatment-associated toxicity, and the optimal sequencing of subsequent HER2-targeted therapies after first-line T-DXd exposure has not been established. The practical challenge is therefore to determine how this effective new strategy should be integrated into individualized treatment decisions.

A New First-Line Standard Challenges the CLEOPATRA Paradigm

For more than a decade, THP has served as the principal first-line treatment approach for HER2-positive metastatic breast cancer. The CLEOPATRA trial established the benefit of adding pertuzumab to trastuzumab and docetaxel, demonstrating substantial improvements in PFS and OS.

An important advantage of the THP strategy is its treatment structure. Patients generally receive a finite course of taxane chemotherapy, followed by maintenance HER2-directed antibodies, with endocrine therapy incorporated for hormone receptor-positive disease when appropriate.

This approach allows patients who achieve disease control to discontinue cytotoxic chemotherapy while maintaining HER2 pathway suppression. However, recurrence and treatment resistance remain common, and increasing evidence supports the earlier use of antibody-drug conjugates (ADCs).

T-DXd combines a HER2-directed antibody with a cleavable linker and a potent topoisomerase I inhibitor payload. Its ability to deliver intracellular cytotoxic therapy, together with a potential bystander effect, has produced substantial activity across multiple HER2-expressing breast cancer populations.

Combining T-DXd with pertuzumab provides simultaneous HER2-directed payload delivery and inhibition of HER2 dimerization. DESTINY-Breast09 was designed to determine whether this approach could improve first-line outcomes compared with conventional THP.

Read About CLEOPATRA Trial on OncoDaily

DESTINY-Breast09: Design and Principal Findings

DESTINY-Breast09 (NCT04784715) was a global, randomized, three-arm phase III trial enrolling 1,157 adults with unresectable or metastatic HER2-positive breast cancer. HER2 positivity was defined as immunohistochemistry (IHC) 3+ or HER2 amplification confirmed by in situ hybridization.

Patients had not previously received chemotherapy or HER2-directed therapy for advanced disease. Prior neoadjuvant or adjuvant HER2-directed therapy was permitted when recurrence occurred more than six months after treatment completion, while one prior line of endocrine therapy for metastatic disease was allowed.

Participants were randomized to T-DXd plus pertuzumab, T-DXd plus placebo, or THP. The prespecified interim analysis compared T-DXd plus pertuzumab (n=383) with THP (n=387). Results from the T-DXd monotherapy arm remained blinded.

The primary endpoint was PFS assessed by blinded independent central review. At the February 26, 2025, cutoff, median PFS was 40.7 months with T-DXd plus pertuzumab versus 26.9 months with THP. Two-year PFS rates were 70.1% versus 52.1%, respectively.

Confirmed objective response rates were 85.1% and 78.6%, with complete responses in 15.1% and 8.5%. Median duration of response reached 39.2 months versus 26.4 months. These findings establish both greater disease control and more durable responses with the ADC-based combination.

However, the OS analysis remained immature, with approximately 16% of patients across the two reported treatment arms having died at the time of the PFS analysis. Consequently, the trial demonstrates a statistically significant PFS advantage but does not yet establish an overall survival advantage.

Risk-Adapted Treatment Selection: Beyond a Universal Algorithm

The central clinical implication of DESTINY-Breast09 is that T-DXd plus pertuzumab provides substantial benefit across multiple patient subgroups. However, risk-adapted treatment should not be confused with an established biomarker-driven algorithm that restricts the regimen to patients with particularly aggressive disease.

The available evidence does not identify a subgroup in which THP is demonstrably superior or in which the benefit of T-DXd plus pertuzumab disappears. Rather, risk adaptation involves balancing the expected magnitude and durability of disease control against individual toxicity risks, treatment goals, comorbidities, and patient preferences.

For patients with rapidly progressive or symptomatic visceral disease, a highly active regimen capable of producing deep and durable responses is particularly attractive.

In contrast, patients with indolent disease, limited tumor burden, significant pulmonary comorbidity, or concerns about prolonged ADC exposure may prioritize a treatment strategy with a finite taxane induction phase and established maintenance options.

These considerations can reasonably influence shared decision-making, but they are clinical judgments rather than subgroup-specific treatment rules validated by DESTINY-Breast09.

Visceral Disease and High Tumor Burden: Prioritizing Durable Disease Control

Patients with extensive visceral involvement may require treatment capable of achieving rapid and sustained tumor reduction. DESTINY-Breast09 demonstrated a high overall response rate and prolonged response duration, supporting its consideration when substantial systemic disease control is a priority.

An exploratory analysis presented at ASCO 2026 provided additional information about the timing of response. Among patients achieving a partial response with T-DXd plus pertuzumab, the median time to response was approximately 1.5 months.

The median time to complete response was longer, at approximately 8.4 months, while the median time to maximum tumor reduction in the overall treatment population was approximately 11 months. These observations suggest that initial tumor reduction may occur relatively early, while deeper responses can develop with continued treatment.

However, these response kinetics do not prove superiority over THP in patients with an immediate visceral crisis, nor do they establish that T-DXd plus pertuzumab is the preferred approach in every emergency clinical situation.

Patients with organ-threatening disease require individualized assessment of performance status, hepatic and pulmonary function, tumor-related complications, and anticipated treatment tolerability. For those suitable for an ADC-based regimen, the substantial response durability demonstrated in DESTINY-Breast09 provides a strong rationale for treatment consideration.

Hormone Receptor Status Does Not Eliminate the Benefit

Approximately 53%–54% of patients included in the primary comparison had hormone receptor-positive disease. A subgroup analysis presented at ESMO 2025 demonstrated that the PFS benefit of T-DXd plus pertuzumab was maintained across hormone receptor categories.

In HR-positive disease, median PFS was 38.0 months with T-DXd plus pertuzumab versus 27.7 months with THP (HR 0.61; 95% CI 0.44–0.84). In HR-negative disease, median PFS was 40.7 versus 22.6 months (HR 0.52; 95% CI 0.37–0.73).

These findings support the use of T-DXd plus pertuzumab irrespective of hormone receptor status. However, hormone receptor positivity remains highly relevant when considering long-term treatment strategy.

For patients receiving THP induction, endocrine therapy can be incorporated into HER2-directed maintenance treatment. The phase III PATINA trial demonstrated that adding palbociclib to maintenance anti-HER2 therapy and endocrine therapy significantly improved PFS in HR-positive/HER2-positive advanced breast cancer.

These findings supported US FDA approval of palbociclib-containing maintenance therapy in June 2026. Importantly, PATINA enrolled patients without progression following taxane-based HER2-directed induction treatment.

Its findings do not establish that palbociclib should be added routinely to ongoing T-DXd plus pertuzumab.

Thus, HR-positive disease presents two increasingly distinct strategies: continuous ADC-based first-line treatment or conventional induction followed by endocrine-containing HER2 maintenance, potentially with CDK4/6 inhibition. No randomized trial has directly compared these complete modern treatment sequences.

Brain Metastases: ESMO 2026 Adds Important Intracranial Evidence

Central nervous system involvement is one of the most consequential clinical considerations in HER2-positive metastatic breast cancer. At ESMO Congress 2026, Cristina Saura and colleagues presented an exploratory analysis of DESTINY-Breast09 evaluating patients with baseline brain metastases.

The analysis included 61 patients with centrally identified brain metastases and at least one postbaseline brain scan: 31 treated with T-DXd plus pertuzumab and 30 receiving THP. Median systemic PFS reached 36.5 months with T-DXd plus pertuzumab compared with 11.1 months with THP (HR 0.30; 95% CI 0.14–0.60).

The intracranial findings were particularly notable. Median CNS-PFS was not estimable with T-DXd plus pertuzumab compared with 9.7 months with THP, corresponding to an HR of 0.26 (95% CI 0.11–0.57). Confirmed CNS objective response rates were 51.6% and 26.7%, respectively. Intracranial complete responses occurred in 35.5% versus 23.3%.

These findings strengthen the evidence supporting first-line T-DXd plus pertuzumab in patients with baseline brain metastases. However, important limitations remain.

The analysis involved a small subgroup and was exploratory. Moreover, patients with clinically active or symptomatic CNS metastases were excluded from the trial, while clinically inactive or appropriately treated lesions could be included.

The findings should therefore not be extrapolated automatically to patients with uncontrolled neurological symptoms, urgent mass effect, or leptomeningeal disease.

In such circumstances, local treatment and multidisciplinary CNS assessment remain essential. For selected patients with stable or asymptomatic brain metastases, the 2026 data provide a compelling additional argument for T-DXd plus pertuzumab.

Read About DESTINY Breast Trials on OncoDaily

De Novo Versus Recurrent Disease: Consistent Benefit Across Disease History

Disease presentation may influence prognosis, prior treatment exposure, and expectations for subsequent therapy. In the ESMO subgroup analysis, the PFS benefit of T-DXd plus pertuzumab was observed in both de novo and recurrent metastatic breast cancer.

For de novo disease, the HR was 0.49 (95% CI 0.35–0.70), while recurrent disease demonstrated an HR of 0.63 (95% CI 0.46–0.87). Similarly, exploratory analyses showed benefit in tumors with and without PIK3CA mutations, with HRs of 0.52 and 0.57, respectively.

These findings suggest that the efficacy advantage is not confined to a single molecular or clinical subgroup. However, subgroup differences should not be interpreted as evidence of differential treatment sensitivity without appropriate interaction testing.

At present, neither PIK3CA mutation status nor hormone receptor expression provides a validated reason to withhold T-DXd plus pertuzumab from an otherwise eligible patient. An important limitation concerns patients who relapse during or shortly after adjuvant HER2-targeted treatment.

DESTINY-Breast09 required more than six months between prior neoadjuvant or adjuvant HER2-targeted therapy and metastatic diagnosis.

Consequently, patients experiencing very early recurrence after contemporary adjuvant T-DM1 or T-DXd may require a different treatment assessment, and the findings should not be generalized without considering prior exposure.

Toxicity Remains Central to Treatment Selection

The principal clinical trade-off is the balance between prolonged disease control and cumulative treatment toxicity. Grade 3 or higher treatment-emergent adverse events occurred in 63.5% of patients receiving T-DXd plus pertuzumab and 62.3% receiving THP.

Although the overall incidence of severe adverse events was similar, the toxicity profiles differed. Nausea, vomiting, fatigue, anemia, hypokalemia, and other hematologic or gastrointestinal adverse events were important considerations with T-DXd plus pertuzumab.

THP was more strongly associated with taxane-related adverse events, including peripheral neuropathy and certain hematologic complications.

Patient-reported outcomes also suggested greater deterioration in nausea, constipation, and appetite-related symptoms with T-DXd plus pertuzumab, while some skin and mucosal symptoms were less frequent.

The most clinically important safety concern remains interstitial lung disease or pneumonitis. In DESTINY-Breast09, adjudicated drug-related ILD/pneumonitis occurred in 12.1% of patients receiving T-DXd plus pertuzumab compared with 1.0% receiving THP.

Most events were grade 1 or 2, but two fatal ILD events occurred in the T-DXd combination group. This risk is particularly relevant when considering prolonged first-line exposure. Patients with previous ILD, active pulmonary inflammatory conditions, or substantial respiratory comorbidity require careful evaluation before treatment.

DESTINY-Breast09 excluded patients with active or previous documented ILD/pneumonitis or suspected ILD that could not be ruled out at screening.

Clinical management should include baseline pulmonary assessment when appropriate, active surveillance for respiratory symptoms, and prompt investigation of new cough, dyspnea, fever, or radiological abnormalities.

According to current T-DXd prescribing information, grade 1 drug-related ILD requires treatment interruption until resolution, while grade 2 or higher ILD requires permanent discontinuation and prompt corticosteroid treatment.

Monitoring also includes complete blood counts, cardiac function where indicated, and proactive management of nausea and other treatment-related toxicities. The ability to recognize and manage complications early is therefore an essential component of successful long-term treatment.

Treatment Duration: Should T-DXd Stop After a Deep Response?

An important unanswered question concerns the optimal duration of ADC exposure. In DESTINY-Breast09, T-DXd plus pertuzumab was administered every three weeks until disease progression or unacceptable toxicity.

This differs from the traditional THP approach, where taxane chemotherapy may be discontinued after an induction phase while HER2-targeted maintenance continues. Exploratory data presented at ASCO 2026 suggested that complete responses and maximum tumor reduction frequently developed after prolonged treatment.

Patients achieving complete or partial responses generally remained on therapy longer than those with stable or progressive disease. These observations suggest that sustained treatment can produce additional tumor regression.

However, they do not establish that indefinite full-dose ADC exposure is necessary for every patient who achieves deep remission. Similarly, they do not validate elective discontinuation of T-DXd after complete response or conversion to pertuzumab–trastuzumab maintenance.

The current evidence supports continuing treatment according to the approved regimen while individualizing interruptions or dose reductions for toxicity. Prospective research is needed to determine whether response-adapted maintenance approaches can preserve efficacy while reducing long-term treatment burden.

Maintenance Strategies Create a New Treatment-Sequence Question

The increasing use of T-DXd in the first-line setting must also be considered alongside recent progress in HER2-directed maintenance treatment.

In addition to PATINA, the phase III HER2CLIMB-05 trial demonstrated that adding tucatinib to trastuzumab and pertuzumab maintenance significantly improved PFS following taxane-based induction therapy.

Median PFS reached 24.9 months with tucatinib-containing maintenance versus 16.3 months with trastuzumab–pertuzumab maintenance alone (HR 0.64). These findings supported US FDA approval in October 2026. However, the HER2CLIMB-05 PFS endpoint was measured after patients completed induction and entered maintenance randomization.

It therefore cannot be directly compared with DESTINY-Breast09 median PFS measured from first-line randomization. Neither PATINA nor HER2CLIMB-05 establishes the safety or efficacy of routinely adding palbociclib or tucatinib to ongoing T-DXd plus pertuzumab.

This distinction is critical because the development of effective maintenance options means that clinicians are increasingly comparing entire treatment sequences, not simply the activity of initial drug combinations.

The optimal strategy after first-line T-DXd plus pertuzumab remains incompletely defined, particularly regarding subsequent use of tucatinib-based treatment, T-DM1, or other emerging HER2-directed agents.

Read About HER2CLIMB-05 Trial on OncoDaily

A Practical Risk-Adapted Framework for First-Line Decisions

The strongest evidence supporting T-DXd plus pertuzumab is the substantial and consistent PFS improvement demonstrated in DESTINY-Breast09.

For a patient with confirmed HER2-positive metastatic disease, adequate performance status, no contraindication to T-DXd, and a priority for maximizing the duration of first-line disease control, the combination is an important evidence-based option.

Patients with substantial visceral disease or stable brain metastases may have particularly compelling clinical reasons to consider its high response activity and encouraging intracranial efficacy. However, this does not mean that patients with less aggressive disease derive no benefit.

The trial’s subgroup findings support efficacy across HR-positive and HR-negative disease, de novo and recurrent presentation, and PIK3CA mutation categories.

For patients with substantial pulmonary risk, difficulty tolerating prolonged ADC treatment, or a strong preference for finite chemotherapy induction, THP followed by an appropriate HER2-directed maintenance strategy remains a clinically relevant alternative.

For HR-positive disease, the opportunity to incorporate endocrine treatment and approved maintenance intensification further influences treatment planning.

For patients with active symptomatic brain metastases, rapidly deteriorating performance status, or very early recurrence after adjuvant ADC exposure, the evidence is less directly applicable, and treatment should be individualized through multidisciplinary assessment.

Ultimately, risk adaptation should balance treatment efficacy, safety, prior exposure, CNS status, comorbidities, patient priorities, and the feasibility of subsequent treatment. It should not rely on unvalidated assumptions that only patients with the highest disease burden require the most effective regimen.

OncoDaily Takeaway

DESTINY-Breast09 has established T-DXd plus pertuzumab as a major advance in first-line HER2-positive metastatic breast cancer, extending median PFS to 40.7 months compared with 26.9 months with THP.

The efficacy benefit is consistent across major clinical and molecular subgroups, and the exploratory ESMO 2026 CNS analysis provides additional support for its use in selected patients with baseline brain metastases. However, the regimen introduces important treatment-selection considerations.

The risk of ILD/pneumonitis, including rare fatal events, requires careful patient assessment and long-term monitoring. Meanwhile, overall survival remains immature, and the optimal management of patients after prolonged first-line ADC exposure is not established.

The availability of PATINA- and HER2CLIMB-05-based maintenance strategies also creates new questions about how continuous ADC treatment should be compared with finite chemotherapy induction followed by targeted maintenance.

The central clinical message is that risk-adapted care should not restrict T-DXd plus pertuzumab to a narrowly defined high-risk subgroup. Instead, it should individualize the use of a broadly effective first-line regimen according to patient-specific benefit, toxicity risk, CNS involvement, and long-term treatment goals.

The next phase of research must determine how to preserve the substantial disease-control benefit achieved with T-DXd plus pertuzumab while improving safety, optimizing maintenance, and establishing effective therapeutic sequencing after progression.

Sources

1. Tolaney SM, Jiang Z, Zhang Q, et al. Trastuzumab Deruxtecan Plus Pertuzumab for HER2-Positive Metastatic Breast Cancer. New England Journal of Medicine. 2026;394:551–562. DOI: 10.1056/NEJMoa2508668.
2. DESTINY-Breast09. ESMO Congress 2025, LBA18. Additional analyses by hormone receptor status, PIK3CA mutation, and disease history.
3. Park YH, et al. DESTINY-Breast09 analysis of treatment duration and clinical outcomes by best response. ASCO Annual Meeting 2026, Abstract 1021.
4. Saura C, et al. DESTINY-Breast09 analysis in patients with baseline brain metastases. ESMO Congress 2026, LBA49.
5. US Food and Drug Administration. Approval of T-DXd plus pertuzumab for first-line HER2-positive metastatic breast cancer. December 15, 2025.
6. European Commission. First-line approval of T-DXd plus pertuzumab for HER2-positive metastatic breast cancer. September 1, 2026.
7. PATINA and HER2CLIMB-05 phase III studies and corresponding US FDA maintenance approvals, June and October 2026.
8. ESMO Clinical Practice Guidelines for Metastatic Breast Cancer. Annals of Oncology. 2026.